Non-Hodgkin Lymphoma

Black and Hispanic patients who received chimeric antigen receptor T-cell therapy for relapsed or refractory non-Hodgkin lymphoma achieved similar efficacy outcomes as white and Asian individuals, according to study results.

A bispecific chimeric antigen receptor T-cell therapy continues to show promising efficacy for patients with relapsed or refractory B-cell non-Hodgkin lymphoma, results of a phase 1/phase 2 trial suggest.

The FDA granted fast track designation to ADI-001 for the treatment of relapsed or refractory B-cell non-Hodgkin lymphoma.

Early phase 1 trial results using an investigational chimeric antigen receptor T-cell therapy manufactured at University of Colorado show encouraging efficacy for adults with relapsed or refractory B-cell non-Hodgkin lymphoma.

Early intrathecal therapy effectively resolved symptoms related to high-grade neurotoxicity among patients who received chimeric antigen receptor T-cell therapy for non-Hodgkin lymphoma, according to a research letter in JAMA Oncology.

In vitro and in vivo evidence has suggested that aspirin may have an antitumor effect, and several studies revealed longer survival in patients with breast cancer who used aspirin regularly compared with nonusers, according to researchers.

Second-line therapy with axicabtagene ciloleucel conferred a greater than eightfold increase in median EFS compared with standard-of-care treatment for older patients with diffuse large B-cell lymphoma, according to phase 3 study results.

Since the approval of the first chimeric antigen receptor T-cell therapy, the research community has grappled with a crucial question.

The FDA granted fast track and regenerative medicine advanced therapy designations to C-CAR039, a chimeric antigen receptor T-cell therapy in development for treatment of relapsed or refractory diffuse large B cell lymphoma.

An enhanced lymphodepletion regimen followed by chimeric antigen receptor T-cell therapy induced response among patients with relapsed or refractory B-cell malignancies, according to results presented at ASH Annual Meeting and Exposition.